Acute bronchitis primary prevention: Difference between revisions
Jump to navigation
Jump to search
m (Robot: Changing Category:Disease state to Category:Disease) |
m (Robot: Changing Category:Mature chapter to Category:Overview complete) |
||
Line 24: | Line 24: | ||
[[Category:General practice]] | [[Category:General practice]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category: | [[Category:Overview complete]] |
Revision as of 18:25, 17 April 2012
Acute bronchitis Microchapters |
Diagnosis |
Treatment |
Acute bronchitis primary prevention On the Web |
American Roentgen Ray Society Images of Acute bronchitis primary prevention |
Risk calculators and risk factors for Acute bronchitis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Onset can be mitigated through various prevention methodologies. Vaccinations serve to as an effective mechanism for primary prevention.
Prevention
In 1985, University of Newcastle, Australia Professor Robert Clancy developed an oral vaccine for acute bronchitis. This vaccine was commercialized four years later as Broncostat.[1]
References
- ↑ Broncostat. Biotechnology.com. Retrieved on October 3 2007.